Literature DB >> 27168275

Apremilast and Secukinumab Combined Therapy in a Patient With Recalcitrant Plaque Psoriasis.

Brooke E Rothstein, Brianna McQuade, Jacqueline E Greb, Ari M Goldminz, Alice B Gottlieb.   

Abstract

We report a 67-year-old Caucasian man with a long-term history of recalcitrant plaque psoriasis and psoriatic arthritis who was initiated on a treatment regimen of apremilast and secukinumab after failing multiple topical, photo, and systemic therapies. This combination provided significant skin improvement with minimal drug side effects. <br /><br /> <em>J Drugs Dermatol. </em>2016;15(5):648-649.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27168275

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN： 1545-9616            Impact factor:   2.114


  5 in total

1.  Interleukin-17 Inhibitor Combination Therapies for the Treatment of Psoriasis: A Systematic Review.

Authors:  Amylee Martin; Akshitha Thatiparthi; Jeffrey Liu; Jashin J Wu
Journal:  J Clin Aesthet Dermatol       Date:  2022-06

2.  Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review.

Authors:  Mette Gyldenløve; Farzad Alinaghi; Claus Zachariae; Lone Skov; Alexander Egeberg
Journal:  Am J Clin Dermatol       Date:  2022-06-23       Impact factor: 6.233

3.  Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy.

Authors:  Marco Galluzzo; Simone D'Adamio; Elena Campione; Luca Bianchi; Marina Talamonti
Journal:  Mol Diagn Ther       Date:  2018-12       Impact factor: 4.074

4.  Optimizing Secukinumab Treatment in Psoriasis with Concomitant Methotrexate Administration: Minireview and A Case Report.

Authors:  Dimitra Kostaki; Emilia Aquila; Laura Macaluso; Carlo Mattozzi; Antonio Giovanni Richetta
Journal:  Case Rep Dermatol       Date:  2019-09-23

5.  Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching.

Authors:  Giovanni Damiani; Giulia Odorici; Alessia Pacifico; Aldo Morrone; Rosalynn R Z Conic; Tima Davidson; Abdulla Watad; Paolo D M Pigatto; Delia Colombo; Piergiorgio Malagoli; Marco Fiore
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.